Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company based in Bothell, Washington. The company is primarily focused on the development and commercialization of cytisinicline, a plant-based alkaloid designed to treat nicotine dependence. Its clinical programs target both traditional smoking cessation and e-cigarette (vaping) cessation.
Not applicable. Achieve Life Sciences is a pre-revenue, late-stage clinical specialty pharmaceutical company; its sole product candidate, cytisinicline, has not been approved by the FDA and generates no product revenue, so there is no customer or product concentration to disclose. As of December 31, 2025 the company had 28 employees.